C1741817_interactsWith_C4550163 | Knowledge4COVID-19

Property	Value
?:effect	<https://research.tib.eu/covid-19/entity/C0001688>
?:hasPrimarySource	<https://research.tib.eu/covid-19/SourceName/UMLS>
?:impact	increase
?:interaction	The risk or severity of adverse effects can be increased when Adecatumumab is combined with Tezepelumab.
?:objectDrug	<https://research.tib.eu/covid-19/entity/C4550163>
?:object_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB15090>
?:precipitantDrug	<https://research.tib.eu/covid-19/entity/C1741817>
?:precipitant_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB05006>
is ?:subClassOf of	<https://research.tib.eu/covid-19/entity/C1741817_hasPharmacodynamic_C4550163>
?:type	<https://research.tib.eu/covid-19/vocab/DrugDrugInteraction>

Metadata

Anon_0

expand all